Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1945 7
1946 26
1947 21
1948 30
1949 12
1950 8
1951 85
1952 180
1953 238
1954 219
1955 192
1956 282
1957 307
1958 214
1959 106
1960 16
1961 17
1962 12
1963 26
1964 42
1965 211
1966 354
1967 428
1968 538
1969 702
1970 793
1971 956
1972 1047
1973 1192
1974 1222
1975 1110
1976 1015
1977 940
1978 915
1979 963
1980 911
1981 1007
1982 1092
1983 1032
1984 1159
1985 1162
1986 1098
1987 1042
1988 1093
1989 1156
1990 1312
1991 1208
1992 1221
1993 1246
1994 1195
1995 1362
1996 1310
1997 1347
1998 1451
1999 1348
2000 1397
2001 1413
2002 1508
2003 1642
2004 1723
2005 1748
2006 1943
2007 2005
2008 2078
2009 2192
2010 2318
2011 2493
2012 2582
2013 2609
2014 2838
2015 2827
2016 2822
2017 2875
2018 2924
2019 2851
2020 2746
2021 2458
2022 2270
2023 1728
2024 635

Text availability

Article attribute

Article type

Publication date

Search Results

86,691 results

Results by year

Filters applied: . Clear all
Page 1
Avacopan: First Approval.
Lee A. Lee A. Drugs. 2022 Jan;82(1):79-85. doi: 10.1007/s40265-021-01643-6. Drugs. 2022. PMID: 34826105 Review.
Avacopan (TAVNEOS) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. The therapeutic effects of avacopan are attributed to the in …
Avacopan (TAVNEOS) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases includin …
N,N-dimethylaniline.
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risks Hum. 1993;57:337-50. IARC Monogr Eval Carcinog Risks Hum. 1993. PMID: 8207864 Free PMC article. Review. No abstract available.
2,6-Dimethylaniline (2,6-xylidine).
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risks Hum. 1993;57:323-35. IARC Monogr Eval Carcinog Risks Hum. 1993. PMID: 8207863 Free PMC article. Review. No abstract available.
para-Chloroaniline.
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risks Hum. 1993;57:305-21. IARC Monogr Eval Carcinog Risks Hum. 1993. PMID: 8207862 Free PMC article. Review. No abstract available.
A Novel Aniline Derivative from Peganum harmala L. Promoted Apoptosis via Activating PI3K/AKT/mTOR-Mediated Autophagy in Non-Small Cell Lung Cancer Cells.
Wu Z, Li W, Tang Q, Huang L, Zhan Z, Li Y, Wang G, Dai X, Zhang Y. Wu Z, et al. Int J Mol Sci. 2023 Aug 10;24(16):12626. doi: 10.3390/ijms241612626. Int J Mol Sci. 2023. PMID: 37628807 Free PMC article.
Non-small cell lung cancer (NSCLC) is a common clinical malignant tumor with limited therapeutic drugs. Leading by cytotoxicity against NSCLC cell lines (A549 and PC9), bioactivity-guided isolation of components from Peganum harmala seeds led to the isolation of pegaharoli …
Non-small cell lung cancer (NSCLC) is a common clinical malignant tumor with limited therapeutic drugs. Leading by cytotoxicity again …
Avacopan in the treatment of ANCA-associated vasculitis.
Tesar V, Hruskova Z. Tesar V, et al. Expert Opin Investig Drugs. 2018 May;27(5):491-496. doi: 10.1080/13543784.2018.1472234. Epub 2018 May 8. Expert Opin Investig Drugs. 2018. PMID: 29718732 Review.
Leflunomide and malononitrilamides.
Silva Júnior HT, Morris RE. Silva Júnior HT, et al. Am J Med Sci. 1997 May;313(5):289-301. doi: 10.1097/00000441-199705000-00008. Am J Med Sci. 1997. PMID: 9145039 Free article. Review.
The in vitro and in vivo mechanisms of action of this class of compounds are not defined completely. Several malononitrilamide analogues and A77 1726 inhibit T- and B-cell proliferation, suppress immunoglobulin production, and interfere with cell adhesion. ...Malononitrila …
The in vitro and in vivo mechanisms of action of this class of compounds are not defined completely. Several malononitrilamide analog …
Bisolvon.
[No authors listed] [No authors listed] Drug Ther Bull. 1969 Nov 7;7(23):89-90. Drug Ther Bull. 1969. PMID: 5365833 No abstract available.
Aniline--a 'historical' contact allergen? Current data from the IVDK and review of the literature.
Uter W, Stropp G, Schnuch A, Lessmann H. Uter W, et al. Ann Occup Hyg. 2007 Mar;51(2):219-26. doi: 10.1093/annhyg/mel076. Epub 2006 Nov 28. Ann Occup Hyg. 2007. PMID: 17135213 Review.
OBJECTIVES: To assess whether aniline should be regarded as potential cause of contact allergy (CA). ...However, it may elicit allergic reactions in subjects pre-sensitized to para-substituted amino compounds. In summary, supported by recent experimental evidence em …
OBJECTIVES: To assess whether aniline should be regarded as potential cause of contact allergy (CA). ...However, it may elicit allerg …
Clinical development of IDH1 inhibitors for cancer therapy.
Zarei M, Hue JJ, Hajihassani O, Graor HJ, Katayama ES, Loftus AW, Bajor D, Rothermel LD, Vaziri-Gohar A, Winter JM. Zarei M, et al. Cancer Treat Rev. 2022 Feb;103:102334. doi: 10.1016/j.ctrv.2021.102334. Epub 2021 Dec 28. Cancer Treat Rev. 2022. PMID: 34974243 Review.
Isocitrate dehydrogenase 1 (IDH1) has been investigated as a promising therapeutic target in select cancers with a mutated version of the enzyme (mtIDH1). ...
Isocitrate dehydrogenase 1 (IDH1) has been investigated as a promising therapeutic target in select cancers with a mutated version of …
86,691 results
You have reached the last available page of results. Please see the User Guide for more information.